EP0946180A4 - Procede de stimulation de la formation osseuse - Google Patents

Procede de stimulation de la formation osseuse

Info

Publication number
EP0946180A4
EP0946180A4 EP97945563A EP97945563A EP0946180A4 EP 0946180 A4 EP0946180 A4 EP 0946180A4 EP 97945563 A EP97945563 A EP 97945563A EP 97945563 A EP97945563 A EP 97945563A EP 0946180 A4 EP0946180 A4 EP 0946180A4
Authority
EP
European Patent Office
Prior art keywords
bone formation
stimulating bone
stimulating
formation
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97945563A
Other languages
German (de)
English (en)
Other versions
EP0946180A1 (fr
Inventor
Fred H Drake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0946180A1 publication Critical patent/EP0946180A1/fr
Publication of EP0946180A4 publication Critical patent/EP0946180A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP97945563A 1996-10-07 1997-10-07 Procede de stimulation de la formation osseuse Withdrawn EP0946180A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2776496P 1996-10-07 1996-10-07
US27764P 1996-10-07
PCT/US1997/018178 WO1998015278A1 (fr) 1996-10-07 1997-10-07 Procede de stimulation de la formation osseuse

Publications (2)

Publication Number Publication Date
EP0946180A1 EP0946180A1 (fr) 1999-10-06
EP0946180A4 true EP0946180A4 (fr) 2003-07-23

Family

ID=21839659

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97945563A Withdrawn EP0946180A4 (fr) 1996-10-07 1997-10-07 Procede de stimulation de la formation osseuse

Country Status (3)

Country Link
EP (1) EP0946180A4 (fr)
JP (1) JP2001501951A (fr)
WO (1) WO1998015278A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
US6008213A (en) * 1995-06-29 1999-12-28 Smithkline Beecham Corporation Integrin receptor antagonists
PE122699A1 (es) * 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
IL135189A0 (en) * 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
UA71586C2 (en) * 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
AUPP794898A0 (en) * 1998-12-24 1999-01-28 Garvan Institute Of Medical Research Transgenic animal
EP1150965A4 (fr) 1999-02-03 2002-05-15 Merck & Co Inc Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
EP1198231A1 (fr) 1999-07-21 2002-04-24 American Home Products Corporation Antagonistes bicycliques selectifs contre l'integrine(alpha)v (beta)3
CN1247258C (zh) 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
MXPA04006709A (es) 2002-01-11 2004-10-04 Sankyo Co Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen.
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
EA017864B1 (ru) 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
EP2221308B1 (fr) 2007-11-16 2013-07-10 Ube Industries, Ltd. Composé de benzazépinone
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
AU2010252280A1 (en) 2009-05-25 2012-01-19 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
EP2878339A1 (fr) 2013-12-02 2015-06-03 Siena Biotech S.p.A. Antagonistes SIP3
CN103772273A (zh) * 2014-03-04 2014-05-07 定陶县友帮化工有限公司 2-boc-氨基-3-羟基-5-氯吡啶的合成方法
CN103772272A (zh) * 2014-03-04 2014-05-07 定陶县友帮化工有限公司 2-boc-氨基-3-羟基-5-溴吡啶的合成方法
CN103880739A (zh) * 2014-03-12 2014-06-25 定陶县友帮化工有限公司 一种2-boc-氨基-3-羟基吡啶的合成方法
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169837A (en) * 1991-03-28 1992-12-08 Allelix Biopharmaceuticals Inc. Isolated osteogenic factor
EP0528587A1 (fr) * 1991-08-09 1993-02-24 Merck & Co. Inc. Inhibition de la résorption osseuse causée par osteoclartes utilisant de dérivés phényliques substitués
US5240961A (en) * 1992-07-02 1993-08-31 Shug Austin L Method of treating reduced insulin-like growth factor and bone loss associated with aging
EP0557663A1 (fr) * 1992-02-27 1993-09-01 Delmas, Pierre, Dr. Répartition de fragilité d'os et prédiction de risque de fracture d'ostéoporotique utilisant une détermination quantitative d'ostéocalcine circulante sous-carboxylée
WO1996000574A1 (fr) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Antagonistes du recepteur de la vibronectine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812119A (en) * 1969-11-21 1974-05-21 Ciba Geigy Corp Dibenzocycloheptenes
US5686116A (en) * 1990-01-12 1997-11-11 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of enhancing repair, healing and augmentation of bone implants
JP2935541B2 (ja) * 1990-06-28 1999-08-16 サントリー株式会社 縮合複素環化合物
JPH0792165A (ja) * 1993-09-21 1995-04-07 Hoechst Japan Ltd 骨粗鬆症診断剤
WO1996000730A1 (fr) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Antagonistes du recepteur de la vitronectine
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (fr) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Antagonistes des recepteurs a l'integrine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169837A (en) * 1991-03-28 1992-12-08 Allelix Biopharmaceuticals Inc. Isolated osteogenic factor
EP0528587A1 (fr) * 1991-08-09 1993-02-24 Merck & Co. Inc. Inhibition de la résorption osseuse causée par osteoclartes utilisant de dérivés phényliques substitués
EP0557663A1 (fr) * 1992-02-27 1993-09-01 Delmas, Pierre, Dr. Répartition de fragilité d'os et prédiction de risque de fracture d'ostéoporotique utilisant une détermination quantitative d'ostéocalcine circulante sous-carboxylée
US5240961A (en) * 1992-07-02 1993-08-31 Shug Austin L Method of treating reduced insulin-like growth factor and bone loss associated with aging
WO1996000574A1 (fr) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Antagonistes du recepteur de la vibronectine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9815278A1 *

Also Published As

Publication number Publication date
JP2001501951A (ja) 2001-02-13
EP0946180A1 (fr) 1999-10-06
WO1998015278A1 (fr) 1998-04-16

Similar Documents

Publication Publication Date Title
IL126203A0 (en) Method for treating pain
EP0906104A4 (fr) Procede de traitement de la douleur
HUP9700851A3 (en) Method for producing l-lysin
AU9035498A (en) Method for treating pain
GB2319796B (en) Formation treatment method using deformable particles
GB9617780D0 (en) Method of treatment
IL127620A0 (en) Method for producing therapeutic DNA
IL129761A0 (en) Method for preparing cyclopropylamines
IL126064A0 (en) Method for treating pain
GB9605828D0 (en) Treatment method
HU228235B1 (hu) Eljárás N-szubsztituált 3-hidroxi-pirazolok elõállítására
HUP9802589A3 (en) Bone stimulating factor
AU9034798A (en) Method for treating pain
IL124786A0 (en) Method for treating pain
GB2359316B (en) Formation treatment method using deformable particles
AU2810497A (en) Methods for inducing bone formation
GB9605709D0 (en) Method
GB9714841D0 (en) Treatment method
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
ZA968062B (en) Bone stimulating factor
GB9604739D0 (en) Surgical method
HK1023061A (en) Method for stimulating bone formation
GB9824573D0 (en) Methods for stimulating bone formation
GB9614741D0 (en) Treatment method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990409

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20030605

17Q First examination report despatched

Effective date: 20030901

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040113

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023061

Country of ref document: HK